161292-80-4

Upstream product

• 20587-30-8 5-methyl-2-nitro-benzoic acid methyl ester 
• 1074-82-4 potassium phtalimide 
• 3113-72-2 5-methyl-2-nitrobenzoic acid 
• 88071-91-4 5-bromomethyl-2-nitrobenzoic acid methyl ester 

Downstream Products

• 741228-89-7 methyl 5-(aminomethyl)-2-nitrobenzoate 
• 1253731-97-3 methyl 5-(methylsulfonamidomethyl)-2-nitrobenzoate 
• 1253731-98-4 methyl 2-amino-5-(methylsulfonamidomethyl)benzoate 
• 1253731-99-5 2-amino-5-(methylsulfonamidomethyl)benzoic acid 
• 1253732-00-1 2-amino-5-(methylsulfonamidomethyl)benzamide 
• 1253731-96-2 N-{[2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl]methyl}methanesulfonamide 
• 195717-72-7 {(R)-1-[4-(tert-Butoxycarbonylamino-methyl)-2-(tert-butyl-dimethyl-silanyloxymethyl)-phenylcarbamoyl]-2-naphthalen-2-yl-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 195717-78-3 {3-(tert-Butyl-dimethyl-silanyloxymethyl)-4-[(R)-2-(N',N''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-carbamic acid tert-butyl ester 
• 195717-87-4 5-(tert-Butoxycarbonylamino-methyl)-2-[(R)-2-(N',N''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzoic acid 
• 195717-81-8 {4-[(R)-2-(N',N''-Dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-3-hydroxymethyl-benzyl}-carbamic acid tert-butyl ester 
• 195717-84-1 {4-[(R)-2-(N',N''-Dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-3-formyl-benzyl}-carbamic acid tert-butyl ester 
• 195717-75-0 [4-((R)-2-Amino-3-naphthalen-2-yl-propionylamino)-3-(tert-butyl-dimethyl-silanyloxymethyl)-benzyl]-carbamic acid tert-butyl ester 
• 195717-70-5 [4-Amino-3-(tert-butyl-dimethyl-silanyloxymethyl)-benzyl]-carbamic acid tert-butyl ester 
• 161292-57-5 methyl 2-amino-5-({[(1,1-dimethylethoxy)carbonyl]amino}methyl)benzoate 

Relevant academic research and scientific papers

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

TRICYCLIC QUINOXALINEDIONE DERIVATIVES

A tricyclic quinoxalinedione derivative represented by the formula 1: STR1 wherein X represents hydrogen, alkyl, halogen, cyano, trifluoromethyl, or nitro;R 1 represents hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl;G represents--CONR 2--or--NR 2 CO--, wherein R 2 represents hydrogen or alkyl;J represents an acidic group or a group which is convertible thereto in vivo;E represents an basic group or a group which is convertible thereto in vivo;Y represents a single bond, alkylene, alkenylene, substituted alkylene, or Y 1--Q--Y 2, wherein Y 1 represents a single bond or alkylene, Y 2 represents alkylene, and Q represents a heteroatom selected from oxygen or sulfur;Z represents alkylene, or a pharmaceutically acceptable salt thereof, these compounds are selective antagonists of glycine binding site of the NMDA receptor.

Nonpeptide bradykinin antagonist analogs based on a model of a sterling-winthrop nonpeptide bradykinin antagonist overlapped with cyclic hexapeptide bradykinin antagonist peptides

A proposed overlap between cyclic hexapeptide Bradykinin antagonists and nonpeptide Bradykinin antagonists is discussed. Structural variations on both the peptides and nonpeptides support the proposed overlap based on an increase or decrease in the biological activities of the antagonists.